Navigation Links
Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Date:12/7/2011

MINNEAPOLIS, Dec. 7, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the Oppenheimer 22nd Annual Healthcare Conference at 2:10 PM ET on Tuesday, December 13, 2011 at The Waldorf Astoria Hotel in New York.

Attendance at the conference is by invitation only.  A live audio webcast of the presentation will be broadcast via the Internet.  Those interested in listening to the webcast may access it at http://www.veracast.com/webcasts/opco/healthcare2011/90116388.cfm or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

 

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.


 

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140

 

EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349

Chris Gale (Media), 646.201.5431

 


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Uroplasty Reports Third Quarter Fiscal 2009 Results
2. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
3. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
4. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
5. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
6. Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
8. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. VIVUS to Present at the Deutsche Bank BioFEST Conference
10. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
11. Verenium to Present at Baird Clean Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)... (PRWEB) , ... February 23, ... ... Inc., announced today that in a published evaluation of multiple immunoassay-based threat ... U.S. Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was ...
(Date:2/23/2017)... , Feb. 23, 2017 Aviva Systems ... announced the acquisition of GenWay Biotech Incorporated, a ... service and product offering for both the research ... facilitate growth and enhance capabilities for both entities. GenWay,s ... ELISA assays will nicely complement ASB,s objective to ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):